A Multicenter, Open-label, Randomized Phase 3 Study of THIO Sequenced With Cemiplimab (LIBTAYO®) vs Investigator's Choice of Chemotherapy as Third-line Treatment in Advanced/Metastatic NSCLC

THIO is a first-in-class small molecule telomere targeting agent, in development for the treatment of non-small cell lung cancer (NSCLC) in combination with cemiplimab (LIBTAYO®). THIO is preferentially incorporated into telomeres sequence in telomerase-positive cells leading to rapid telomere uncapping, genomic instability, and cell death.
Cemiplimab is a programmed cell death protein 1 (PD-1) inhibitor recently approved as a first-line treatment for patients with locally advanced or metastatic NSCLC with 50% or more PD-L1 expression. It is hypothesized that THIO administration prior to cemiplimab would restore tumor responses to immunotherapy in subjects who either developed resistance or relapsed after receiving first line treatment with an immune check point inhibitor.

Start Date08 Dec 2025

Sponsor / Collaborator

MAIA Biotechnology, Inc.

NCT05208944

/ RecruitingPhase 2

A Multicenter, Open-Label, Dose-Finding, Phase 2 Study Evaluating THIO Sequenced With Cemiplimab (LIBTAYO®) in Subjects With Advanced Non-Small Cell Lung Cancer (NSCLC)

Start Date08 Jun 2022

Sponsor / Collaborator

MAIA Biotechnology, Inc.

NCT01423500

/ Unknown statusPhase 3IIT

Allogeneic Stem Cell Transplantation in Children and Adolescents With Acute Lymphoblastic Leukaemia

With this protocol the ALL-SCT BFM international study group wants
* to evaluate whether hematopoietic stem cell transplantation (HSCT) from matched family or unrelated donors (MD) is equivalent to the HSCT from matched sibling donors (MSD).
* to evaluate the efficacy of hematopoietic stem cell transplantation (HSCT)from mismatched family or unrelated donors (MMD) as compared to HSCT from matched sibling donors or matched donors.
* to determine whether therapy has been carried out according to the main HSCT protocol recommendations. The standardisation of the treatment options during HSCT from different donor types aims at the achievement of an optimal comparison of survival after HSCT with survival after chemotherapy only.
* to prospectively evaluate and compare the incidence of acute and chronic Graft-versus-Host-Disease (GvHD) after HSCT from matched sibling donor (MSD), from matched donor (MD) and from mismatched donor (MMD).

Start Date01 Jan 2007

Sponsor / Collaborator

St Anna Kinderkrebsforschung

100 Clinical Results associated with Ateganosine

100 Translational Medicine associated with Ateganosine

100 Patents (Medical) associated with Ateganosine

182

Literatures (Medical) associated with Ateganosine

01 Aug 2025·NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY

Investigation of the inhibitory effects of the telomere-targeted compounds on glutathione S-transferase P1

Article

Author: Mender, Ilgen ; Bastug, Turgut ; Ozcan, Mehmet ; Gryaznov, Sergei M ; Burus, Ayse ; Dikmen, Z Gunnur ; Bayazit, Yasemin

Abstract:

Glutathione S-transferase P1 (GSTP1) plays a significant role in cancer progression and chemotherapy resistance, with its overexpression diminishing chemotherapeutic efficacy across various tumor types. This study evaluates the inhibitory effects of 6-thio-2′-deoxyguanosine (6-thio-dG) and its dimeric form (6-thio-2′-dG-Dimer) on GSTP1. Enzyme inhibition assays with recombinant human GSTP1, kinetic analysis, molecular docking, and molecular dynamic simulations were employed. Enzymatic assays were performed in 0.1 M phosphate buffer (pH 6.5) at 30 °C, containing 1 mM EDTA, 1 mM GSH, and 1 mM CDNB. The compounds 6-thio-dG and its dimer were dissolved in 2.5% DMSO for the experiments. The IC₅₀ values indicated that the dimer exhibited a higher potency (IC₅₀: 0.339 μM) than the monomer (IC₅₀: 15.14 μM). Kinetic analysis revealed noncompetitive inhibition with glutathione (Ki: 12.26 μM) and mixed inhibition with CDNB (Ki: 11.41 μM) for the monomer, whereas the dimer showed mixed inhibition with glutathione (Ki: 0.972 μM) and competitive inhibition with CDNB (Ki: 0.723 μM). Molecular docking confirmed the higher binding affinity of the dimer (binding energy: − 7.9 kcal/mol, Ki: 1.595 μM) compared to the monomer (binding energy: − 6.2 kcal/mol, Ki: 28.21 μM). The dimer form of 6-thio-dG shows strong potential to enhance chemotherapeutic efficacy by effectively inhibiting GSTP1 and overcoming drug resistance. Its superior inhibitory properties make it a valuable candidate for targeted cancer therapies.Graphical abstract

01 Jul 2025·EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES

Enhancing diagnostic accuracy for periprosthetic joint infections with an alternative homogenization approach

Article

Author: Coorevits, Liselotte ; De Bel, Annelies ; Goes, Sofie ; Boudewijns, Michaël

PURPOSE:

In this study, we assessed the use of two commercial bead mills, ProbeAX (PBX) and ProbeAX Evolution (PBX-E, AxonLab). Additionally, we investigated the application of PBX in routine procedures and evaluated whether extended incubation in enrichment media, such as thioglycolate broths (THIO) and blood culture bottles (BCB), could enhance the microbiological diagnosis of periprosthetic infections (PJI) and fracture-related infections (FRI).

METHODS:

The PBX and PBX-E were evaluated on the quantitative recovery of multiple microorganisms from spiked samples. For the comparison of the three methods, tissue samples from 87 individuals suspected of having PJI or FRI and requiring surgery were included in the study.

RESULTS:

The added value of BCB and THIO, next to conventional culture (CC), was assessed by comparing the sensitivities of each technique, being 87.1% for CC, 96.8% for BCB, and 80.6% for THIO. The contamination rate of THIO (59.8% (52/87)) was significantly higher compared to CC (21.8% (19/87)) and BCB (17.2% (15/87)), resulting in the lowest specificity for THIO (20.0%), followed by CC (67.8%) and BCB (75.4%). The mean time-to-positivity (TTP) for BCB was 2.3 days, for CC 2.5 days, and 7.3 days for THIO (p <.001). Nonetheless, extended incubation was necessary to confirm all infections, particularly those caused by anaerobic bacteria.

CONCLUSION:

This study demonstrates that culturing tissue samples in BCB improves the diagnosis of PJI/FRI. Extended incubation for more than 5 days is only essential for detecting slow-growing bacteria, such as Cutibacterium acnes. Regarding the stability of different bacteria, the novel PBX-E demonstrated superior results. Time until inoculation, however, is critical to ensure optimal recovery.

01 Mar 2025·Acta Crystallographica Section C-Structural Chemistry

Synthesis and crystal structure of a nickel(II) 2′-deoxy-6-thioguanosine nitrate complex

Article

Author: Harrington, Ross W ; Pike, Andrew R ; Clegg, William ; Hribesh, Samira O ; Houlton, Andrew

The reaction of Ni(NO3)2·6H2O with the thio-modified nucleoside 2′-deoxy-6-thioguanosine (d-tG, C10H13N5O3S) in methanol in a 1:1.3 stoichiometric ratio deposited the title compound, [Ni(d-tG)3](NO3)2·2H2O, as green crystals. Despite the <1:3 Ni–ligand ratio used in the synthesis, the deoxy-thioguanosine binds to form three N7,S6-coordinated five-membered chelate rings with individual NiII ions in mononuclear complexes rather than bridge metal centres into more extended oligomeric or polymeric structures.

News (Medical) associated with Ateganosine

24 Dec 2025

·www.globenewswire.com

MAIA Biotechnology Board Members Continue to Participate in Private Placement Financings

Purchases reflect strong confidence in the scientific differentiation and commercial potential of ateganosine CHICAGO, Dec. 24, 2025 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today announced that independent directors including Adelina Louie Ngar Yee and Stan V. Smith, Ph.D. purchased common stock and warrants in the recent private placement offering which closed on December 22, 2025. Three directors purchased a total of 179,737 shares and 179,737 warrants with an average purchase price of $1.224. Dr. Smith has invested in all of MAIA’s funding rounds since the Company’s inception in 2018, and Ms. Adelina Louie is a top investor in MAIA. Gross proceeds from the offering totaled approximately $1.51 million. To date, directors and officers hold 5,019,857 shares or 13.43% of MAIA. “Ongoing support from our directors reflects their strong conviction in the commercial potential of ateganosine, our first-in-class anticancer treatment for advanced non-small cell lung cancer (NSCLC),” said Vlad Vitoc, M.D., founder and CEO of MAIA. “Consistent insider participation in our 2025 financings strengthens our ability to execute as we advance our pivotal Phase 3 international trial launched this month with first patient dosing.” Dr. Smith commented, “Our continued support reflects our strong confidence in the scientific differentiation and commercial promise of ateganosine. The initiation of the pivotal Phase 3 trial marks an important value-creation milestone for MAIA.” Ms. Adelina Louie stated, “I believe MAIA has reached a pivotal stage in advancing life-changing therapies to broad populations of patients with cancer, and I am proud continue to support the Company in my capacity as both an investor and a member of the Board.” The U.S. Food and Drug Administration (FDA) has granted Fast Track designation for ateganosine for the treatment of NSCLC. Statistical assessments of the Phase 3 trial point to a very high probability of technical success for regulatory approval of ateganosine. About Ateganosine Ateganosine (THIO, 6-thio-dG or 6-thio-2’-deoxyguanosine) is a first-in-class investigational telomere-targeting agent currently in clinical development to evaluate its activity in non-small cell lung cancer (NSCLC). Telomeres, along with the enzyme telomerase, play a fundamental role in the survival of cancer cells and their resistance to current therapies. The modified nucleotide 6-thio-2’-deoxyguanosine induces telomerase-dependent telomeric DNA modification, DNA damage responses, and selective cancer cell death. Ateganosine-damaged telomeric fragments accumulate in cytosolic micronuclei and activates both innate (cGAS/STING) and adaptive (T-cell) immune responses. The sequential treatment of ateganosine followed by PD-(L)1 inhibitors resulted in profound and persistent tumor regression in advanced, in vivo cancer models by induction of cancer type–specific immune memory. Ateganosine is presently developed as a second or later line of treatment for NSCLC for patients that have progressed beyond the standard-of-care regimen of existing checkpoint inhibitors. About MAIA Biotechnology, Inc. MAIA is a targeted therapy, immuno-oncology company focused on the development and commercialization of potential first-in-class drugs with novel mechanisms of action that are intended to meaningfully improve and extend the lives of people with cancer. Our lead program is ateganosine (THIO), a potential first-in-class cancer telomere targeting agent in clinical development for the treatment of NSCLC patients with telomerase-positive cancer cells. For more information, please visit www.maiabiotech.com. Forward Looking Statements MAIA cautions that all statements, other than statements of historical facts contained in this press release, are forward-looking statements. Forward-looking statements are subject to known and unknown risks, uncertainties, and other factors that may cause our or our industry’s actual results, levels or activity, performance or achievements to be materially different from those anticipated by such statements. The use of words such as “may,” “might,” “will,” “should,” “could,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “project,” “intend,” “future,” “potential,” or “continue,” and other similar expressions are intended to identify forward looking statements. However, the absence of these words does not mean that statements are not forward-looking. For example, all statements we make regarding (i) the initiation, timing, cost, progress and results of our preclinical and clinical studies and our research and development programs, (ii) our ability to advance product candidates into, and successfully complete, clinical studies, (iii) the timing or likelihood of regulatory filings and approvals, (iv) our ability to develop, manufacture and commercialize our product candidates and to improve the manufacturing process, (v) the rate and degree of market acceptance of our product candidates, (vi) the size and growth potential of the markets for our product candidates and our ability to serve those markets, and (vii) our expectations regarding our ability to obtain and maintain intellectual property protection for our product candidates, are forward looking. All forward-looking statements are based on current estimates, assumptions and expectations by our management that, although we believe to be reasonable, are inherently uncertain. Any forward-looking statement expressing an expectation or belief as to future events is expressed in good faith and believed to be reasonable at the time such forward-looking statement is made. However, these statements are not guarantees of future events and are subject to risks and uncertainties and other factors beyond our control that may cause actual results to differ materially from those expressed in any forward-looking statement. Any forward-looking statement speaks only as of the date on which it was made. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law. In this release, unless the context requires otherwise, “MAIA,” “Company,” “we,” “our,” and “us” refers to MAIA Biotechnology, Inc. and its subsidiaries. Investor Relations Contact+1 (872) 270-3518ir@maiabiotech.com

Phase 3Fast TrackImmunotherapy

15 Dec 2025

·www.globenewswire.com

MAIA Biotechnology Announces First Patient Dosed in THIO-104 Phase 3 Pivotal Trial Evaluating Ateganosine as Third-Line Treatment for Advanced Non-Small Cell Lung Cancer

Key milestone achieved as Company advances clinical program to full approval trial of ateganosine sequenced with a checkpoint inhibitor in comparison to chemotherapy Dec. 11, 2025 -- MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today announced that the first patient has been dosed in the Company’s THIO-104 Phase 3 pivotal trial evaluating the efficacy of ateganosine administered in sequence with a checkpoint inhibitor (CPI) as a third-line treatment for advanced non-small cell lung cancer (NSCLC). The multicenter, open-label trial of patients who are resistant to CPI and chemotherapy treatments, is designed to assess overall survival for ateganosine sequenced with a CPI compared to investigator’s choice of chemotherapy in a 1:1 randomization of up to 300 patients. MAIA has received regulatory approval to screen patients in Taiwan, Turkey, select European Medicines Agency (EMA) countries, and Georgia. Screening and enrollment are now underway. “Our strategy to bring our telomere-targeting treatment to market is proceeding according to plan as we advance our ateganosine program to a Phase 3 trial. This larger trial will provide us a robust dataset to support our case for commercial approval by the U.S. FDA,” said Vlad Vitoc, M.D., CEO of MAIA. “We have many sites in several countries already screening patients, and with our first patient dosed, we have achieved a key milestone along our path to potential FDA commercial approval. We expect to see Phase 3 results consistent with Phase 2 trial data showing median survival of 17.8 months compared to approximately six months of survival from chemotherapy. We are confident that ateganosine could become the new treatment standard for patients suffering from this devastating disease.” Ateganosine sequenced with a CPI has shown exceptional efficacy in third-line NSCLC patients. As of September 17, 2025, the observed progression free survival (PFS) in THIO-101 was 5.6 months, more than double the standard of care PFS of 2.5 months. One patient that began therapy in March 2023 has shown survival of 30 months, or 912 days. The U.S. Food and Drug Administration (FDA) has granted Fast Track designation for ateganosine for the treatment of NSCLC. Ateganosine (THIO, 6-thio-dG or 6-thio-2’-deoxyguanosine) is a first-in-class investigational telomere-targeting agent currently in clinical development to evaluate its activity in non-small cell lung cancer (NSCLC). Telomeres, along with the enzyme telomerase, play a fundamental role in the survival of cancer cells and their resistance to current therapies. The modified nucleotide 6-thio-2’-deoxyguanosine induces telomerase-dependent telomeric DNA modification, DNA damage responses, and selective cancer cell death. Ateganosine-damaged telomeric fragments accumulate in cytosolic micronuclei and activates both innate (cGAS/STING) and adaptive (T-cell) immune responses. The sequential treatment of ateganosine followed by PD-(L)1 inhibitors resulted in profound and persistent tumor regression in advanced, in vivo cancer models by induction of cancer type–specific immune memory. Ateganosine is presently developed as a second or later line of treatment for NSCLC for patients that have progressed beyond the standard-of-care regimen of existing checkpoint inhibitors. THIO-104 is a multicenter, open-label, randomized Phase 3 clinical trial, designed to evaluate ateganosine’s telomere-targeting anti-tumor activity when followed by PD-(L)1 inhibition in patients with advanced third-line NSCLC who previously did not respond or developed resistance to treatment regimens containing checkpoint inhibitor and/or chemotherapy and have progressed. The trial has two primary objectives: (1) to assess the clinical efficacy of ateganosine compared to investigator’s choice of chemotherapy, using median Overall Survival (OS) as the primary clinical endpoint (2) to evaluate the safety and tolerability of ateganosine in sequential combination with a checkpoint inhibitor. For more information on this Phase 3 trial, please visit ClinicalTrials.gov using the identifier NCT06908304. MAIA is a targeted therapy, immuno-oncology company focused on the development and commercialization of potential first-in-class drugs with novel mechanisms of action that are intended to meaningfully improve and extend the lives of people with cancer. Our lead program is ateganosine (THIO), a potential first-in-class cancer telomere targeting agent in clinical development for the treatment of NSCLC patients with telomerase-positive cancer cells. The content above comes from the network. if any infringement, please contact us to modify.

Clinical ResultImmunotherapyFast Track

11 Dec 2025

·www.globenewswire.com

MAIA Leadership Continues Insider Buying in 2025 and Trial Data Signals Breakout Potential

CHICAGO, Dec. 11, 2025 (GLOBE NEWSWIRE) -- A recent round of open-market purchases marks another display of confidence as the small molecule telomere-targeting cancer therapy by MAIA Biotechnology, Inc. (NYSE American: MAIA) advances through mid- to late-stage clinical development. Newly filed disclosures show that CEO Dr. Vlad Vitoc and other board members acquired approximately 182,445 shares between November 21 and 28, 2025. Insiders’ participation has been viewed by the market as a strong signal of alignment, conviction, and belief in the long-term value creation potential of the ateganosine platform. The latest insider buying arrives as ateganosine continues to deliver encouraging results. These outcomes have strengthened internal and external confidence that MAIA’s novel telomere-targeting approach may represent a meaningful new therapeutic pathway for patients with advanced non-small cell lung cancer (NSCLC). Taken together—material insider buying at market prices, sustained insider participation across 2025 financings, and strengthening clinical signals—MAIA’s leadership continues to demonstrate a unified stance: confidence in the company’s strategy, confidence in ateganosine’s growing body of clinical evidence, and confidence in the opportunity ahead as the program advances toward later-stage development. To date, Directors and Officers hold 4,480,120 shares or 12.95% of the company. About MAIA Biotechnology, Inc. MAIA is a targeted therapy, immuno-oncology company focused on the development and commercialization of potential first-in-class drugs with novel mechanisms of action that are intended to meaningfully improve and extend the lives of people with cancer. Our lead program is ateganosine (THIO), a potential first-in-class cancer telomere targeting agent in clinical development for the treatment of NSCLC patients with telomerase-positive cancer cells. For more information, please visit www.maiabiotech.com. Forward Looking Statements MAIA cautions that all statements, other than statements of historical facts contained in this press release, are forward-looking statements. Forward-looking statements are subject to known and unknown risks, uncertainties, and other factors that may cause our or our industry’s actual results, levels or activity, performance or achievements to be materially different from those anticipated by such statements. The use of words such as “may,” “might,” “will,” “should,” “could,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “project,” “intend,” “future,” “potential,” or “continue,” and other similar expressions are intended to identify forward looking statements. However, the absence of these words does not mean that statements are not forward-looking. For example, all statements we make regarding (i) the initiation, timing, cost, progress and results of our preclinical and clinical studies and our research and development programs, (ii) our ability to advance product candidates into, and successfully complete, clinical studies, (iii) the timing or likelihood of regulatory filings and approvals, (iv) our ability to develop, manufacture and commercialize our product candidates and to improve the manufacturing process, (v) the rate and degree of market acceptance of our product candidates, (vi) the size and growth potential of the markets for our product candidates and our ability to serve those markets, and (vii) our expectations regarding our ability to obtain and maintain intellectual property protection for our product candidates, are forward looking. All forward-looking statements are based on current estimates, assumptions and expectations by our management that, although we believe to be reasonable, are inherently uncertain. Any forward-looking statement expressing an expectation or belief as to future events is expressed in good faith and believed to be reasonable at the time such forward-looking statement is made. However, these statements are not guarantees of future events and are subject to risks and uncertainties and other factors beyond our control that may cause actual results to differ materially from those expressed in any forward-looking statement. Any forward-looking statement speaks only as of the date on which it was made. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law. In this release, unless the context requires otherwise, “MAIA,” “Company,” “we,” “our,” and “us” refers to MAIA Biotechnology, Inc. and its subsidiaries. Investor Relations Contact+1 (872) 270-3518ir@maiabiotech.com

100 Deals associated with Ateganosine

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Non-Small Cell Lung Cancer	Phase 3	Poland	MAIA Biotechnology, Inc.	08 Dec 2025
Non-Small Cell Lung Cancer	Phase 3	Romania	MAIA Biotechnology, Inc.	08 Dec 2025
Non-Small Cell Lung Cancer	Phase 3	Taiwan Province	MAIA Biotechnology, Inc.	08 Dec 2025
Non-Small Cell Lung Cancer	Phase 3	Turkey	MAIA Biotechnology, Inc.	08 Dec 2025
Advanced Lung Non-Small Cell Carcinoma	Phase 2	Australia	MAIA Biotechnology, Inc.	08 Jun 2022
Advanced Lung Non-Small Cell Carcinoma	Phase 2	Bulgaria	MAIA Biotechnology, Inc.	08 Jun 2022
Advanced Lung Non-Small Cell Carcinoma	Phase 2	Hungary	MAIA Biotechnology, Inc.	08 Jun 2022
Advanced Lung Non-Small Cell Carcinoma	Phase 2	Poland	MAIA Biotechnology, Inc.	08 Jun 2022
Advanced Lung Non-Small Cell Carcinoma	Phase 2	Taiwan Province	MAIA Biotechnology, Inc.	08 Jun 2022
Advanced Lung Non-Small Cell Carcinoma	Phase 2	Turkey	MAIA Biotechnology, Inc.	08 Jun 2022

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT05208944 (THIO-101, SITC2025)	Phase 2	-	48	THIO + Cemiplimab	wntjjwvenr(ktplbvdasi) = bfctlfglxt whmpjrzwni (eutuxturif )	Positive	05 Nov 2025
NCT05208944 (THIO-101, GlobeNewswire) Manual	Phase 2	Advanced Lung Non-Small Cell Carcinoma Third line	-	Ateganosine (THIO) 180 mg +cemiplimab	qipoomxeex(djzdwugqgl) = rdktzsolol orpoubflel (milarzchol ) View more	Positive	11 Sep 2025
NCT05208944 (THIO-101, GlobeNewswire) Manual	Phase 2	Advanced Lung Non-Small Cell Carcinoma Third line	-	standard of care treatments	qipoomxeex(djzdwugqgl) = fcbszzxmky orpoubflel (milarzchol )	Positive	11 Sep 2025
NCT05208944 (THIO-101, BusinessWire) Manual	Phase 2	Advanced Lung Non-Small Cell Carcinoma Third line	22	Ateganosine	ayuxghvadw(eyidlbjtky) = djqszfqwhi hmbasqomdt (ucupdpnjsd )	Positive	09 Jul 2025
NCT05208944 (ASCO2025)	Phase 2	Non-Small Cell Lung Cancer Third line PD-L1 expression	79	THIO 180 mg	qocxwignhn(gfrnneyknn) = nnnwxqcchv icqqyumfhf (bfhxaarjtb )	Positive	30 May 2025
NCT05208944 (Phase II study of telomere-targeting agent THIO sequenced by cemiplimab in immune checkpoint inhibitor-resistant advanced NSCLC, ESMO_ELCC2025)	Phase 2	Non-Small Cell Lung Cancer Interleukin-6	12	THIO 180 mg	lkeafqnlhh(pumdjhjinb) = hofbqhwbos czwxufyfyx (ornreqcabx )	Positive	26 Mar 2025
NCT05208944 (THIO-101, BusinessWire) Manual	Phase 2	Advanced Lung Non-Small Cell Carcinoma Third line	22	THIO-101	nhinipyehc(etwrfqsxwl) = ojcnbcugnn eeddwlflcs (axdpggoyij )	Positive	04 Feb 2025
NCT05208944 (THIO-101, BusinessWire) Manual	Phase 2	Advanced Lung Non-Small Cell Carcinoma Third line	22	SOC	nhinipyehc(etwrfqsxwl) = mgknyayhyr eeddwlflcs (axdpggoyij )	Positive	04 Feb 2025
NCT05208944 (THIO-101, SITC2024) Manual	Phase 2	Non-Small Cell Lung Cancer	69	THIO 180mg dose +cemiplimab (3rd-line)	neoktlowlz(zszodboxyg) = kigvvjpssz qlzglnkwds (brbxuncrth ) View more	Positive	06 Nov 2024
NCT05208944 (THIO-101, ASCO2024) Manual	Phase 2	Advanced Lung Non-Small Cell Carcinoma TERT+	70	THIO 60 mg	yevwxflnhm(uymfnjlndf) = Across all pts treated n=70, most AEs were G1/2. The most frequent related AEs were AST increase (23%), ALT increase (20%), and nausea (11%). uzdzvtmaqj (mpwpnaeiru ) View more	Positive	24 May 2024
NCT05208944 (THIO-101, ASCO2024) Manual	Phase 2	Advanced Lung Non-Small Cell Carcinoma TERT+	70	THIO 180 mg		Positive	24 May 2024
NCT05208944 (THIO-101, Biospace) Manual	Phase 2	Non-Small Cell Lung Cancer Third line	-	THIO 180mg + cemiplimab	pujtztnkcm(xzyitlacci) = kijuyuqnbr ovmprmbscp (ooseeprjnc ) View more	Positive	06 Mar 2024
NCT05208944 (THIO-101, Biospace) Manual	Phase 2	Non-Small Cell Lung Cancer	42	THIO-101+Libtayo (second-line)	witfcagaad(wfexwlxpfm) = qjmygeuazl ijzyptpgut (dvzyjwrnwm )	Positive	17 Jan 2024
NCT05208944 (THIO-101, Biospace) Manual	Phase 2	Non-Small Cell Lung Cancer	42	THIO-101+Libtayo (third-line)	witfcagaad(wfexwlxpfm) = lrcgvhdaus ijzyptpgut (dvzyjwrnwm )	Positive	17 Jan 2024

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Ateganosine

Overview

Basic Info

Structure/Sequence

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation